Similar articles

• Therapeutic use of immunotoxins.

  Cobb PW, LeMaistre CF. Cobb PW, et al. Semin Hematol. 1992 Jul;29(3 Suppl 2):6-13. Semin Hematol. 1992. PMID: 1509295 Review.
• Are targeted therapies really targeted?

  Schilsky RL. Schilsky RL. Clin Adv Hematol Oncol. 2003 Dec;1(12):722-3. Clin Adv Hematol Oncol. 2003. PMID: 16258475 No abstract available.
• Serotherapy of cancer.

  Harris DT, Mastrangelo MJ. Harris DT, et al. Semin Oncol. 1989 Jun;16(3):180-98. Semin Oncol. 1989. PMID: 2658082 Review. No abstract available.
• Immunotoxins: selection of cell-surface antigens and their corresponding monoclonal antibodies.

  Bjorn MJ, Villemez CL. Bjorn MJ, et al. Cancer Treat Res. 1988;37:255-77. doi: 10.1007/978-1-4613-1083-9_15. Cancer Treat Res. 1988. PMID: 2908629 Review. No abstract available.
• [Recombinant immunotoxin for cancer therapy: current status and prospective].

  Nagata S. Nagata S. Tanpakushitsu Kakusan Koso. 2001 Mar;46(4 Suppl):540-6. Tanpakushitsu Kakusan Koso. 2001. PMID: 11268658 Review. Japanese. No abstract available.